Who are Aminton's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): R-Gene 10, Cortef, Cortisol, Argimate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aminopicoline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Aminton — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aminton (aminopicoline) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aminopicoline. Area: Hematology.

unknown aminopicoline Nitric oxide synthase, inducible Hematology Live · refreshed every 30 min

Target snapshot

Aminton (aminopicoline). Aminton works by inhibiting the production of nitric oxide through the inhibition of inducible nitric oxide synthase.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aminton TARGET	aminopicoline		unknown	aminopicoline	Nitric oxide synthase, inducible
R-Gene 10	ARGININE	Pfizer	marketed	arginine hydrochloride	Nitric oxide synthase, inducible	1973-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	marketed	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortisol	Cortisol	University of Zurich	marketed		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
Argimate	ARGININE GLUTAMATE		phase 3	arginine glutamate	Nitric oxide synthase, inducible

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-11-19 — Cortef · 9717740 · Method of Use · US
2033-01-10 — Cortef · 9675559 · Method of Use · US
2034-05-12 — Cortef · 9649280 · Formulation · US
2043-02-23 — Cortef · 12133914 · Method of Use · US
2043-02-23 — Cortef · 11904046 · Formulation · US

Sponsor landscape (aminopicoline class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aminton — Competitive Intelligence Brief. https://druglandscape.com/ci/aminopicoline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing